T2S Group to Launch IPO, Marking a New Era for Moroccan Market
T2S Group Holding has received the green light from Morocco's financial market regulatory authority to initiate its initial public offering (IPO) on the Casablanca Stock Exchange. This landmark event will kick-start the country's IPO market for 2026, with an operation valued at up to 1.1 billion dirhams, approximately 110 million dollars. The IPO is structured to include a capital increase of nearly 350 million dirhams alongside the sale of existing shares amounting to around 750 million dirhams. Investors will have the opportunity to subscribe from July 13 to July 17, with trading expected to commence on July 27 under the ticker symbol T2S. The company plans to offer 4.93 million shares at a price of 223 dirhams each, which gives the company an estimated valuation of around 4.86 billion dirhams.
Founded in 1992, T2S specializes in the provision of medical equipment, diagnostic systems, radiopharmaceutical products, and hospital software solutions. The company operates through four subsidiaries, employs over 400 individuals, and collaborates with more than 40 international firms specializing in medical technologies, including GE Healthcare. Its services extend across more than 20 African countries, underscoring its significant regional presence.
In 2025, T2S reported a revenue of 1.76 billion dirhams and a net profit of 211 million dirhams. The company anticipates a revenue growth to 4.17 billion dirhams by 2030, with net profits projected to reach 607 million dirhams. Its expansion plans include new oncology initiatives in Côte d'Ivoire, Mali, and Senegal, along with continued growth in diagnostics and after-sales services. The proceeds from the IPO will be directed towards financing a second cyclotron in Fès, the deployment of diagnostic equipment, the modernization of IT systems, and investments in cybersecurity. Post-IPO, the floating shares will represent about 22.6% of the company's capital, while current majority shareholders will remain subject to lock-up agreements.
Key Takeaways on T2S's Market Entry
T2S's IPO is a crucial step in the ongoing recovery of the Moroccan stock market, following a resurgence of IPOs in 2025. The company operates within the health technology sector, which is experiencing a growing demand for medical equipment, diagnostics, and cancer treatments across Africa, as governments and private providers bolster their healthcare capabilities. Unlike many health sector distributors, T2S integrates the sale of equipment with maintenance, digital hospital systems, and the production of radiopharmaceuticals, securing multiple streams of recurring revenue.
This IPO also reflects an increasing interest among investors in companies with regional expansion strategies rather than those focused solely on Morocco. The planned projects in Côte d'Ivoire, Mali, and Senegal highlight that healthcare infrastructure remains a significant investment opportunity throughout West Africa. For investors, the primary concern will be whether T2S can achieve its growth objectives while maintaining its margins as it expands into new markets and increases its capital expenditures.
Moreover, this IPO reinforces Casablanca's position as one of the most vibrant stock exchanges in Africa for new listings. Following the strong interest generated by SGTM, Vicenne, and Cash Plus among investors in 2025, T2S will serve as a litmus test to determine if this momentum continues into 2026 and whether the Moroccan IPO market can accommodate a growing number of large private companies seeking public capital.
As reported by fr.allafrica.com.
